|
1
|
Hillestad LK: Acute promyelocytic
leukemia. Acta Med Scand. 159:189–194. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bernard J, Mathe G, Boulay J, Ceoard B and
Chome J: Acute promyelocytic leukemia: A study made on 20 cases.
Schweiz Med Wochenschr. 89:604–608. 1959.(In French). PubMed/NCBI
|
|
3
|
Bernard J, Weil M, Boiron M, Jacquillat C,
Flandrin G and Gemon MF: Acute promyelocytic leukemia: Results of
treatment by daunorubicin. Blood. 41:489–496. 1973.PubMed/NCBI
|
|
4
|
Ribeiro RC and Rego E: Management of APL
in developing countries: Epidemiology, challenges and opportunities
for international collaboration. Hematology Am Soc Hematol Educ
Program. 162–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang P, Wang SY, Hu LH, Shi FD, Qiu FG,
Hong ZZ, Han XY, Yang H, Song YZ, Liu YP, et al: Arsenic trioxide
treated 72 cases of acute promyelocytic leukemia. Zhong Hua Xue Ye
Xue Za Zhi. 17:58–60. 1996.(In Chinese).
|
|
6
|
Wang ZY: Ham-Wasserman lecture: Treatment
of acute leukemia by inducing differentiation and apoptosis.
Hematology Am Soc Hematol Educ Program. 1–13. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haverkamp W, Breithardt G, Camm AJ, Janse
MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A
and Shah R: The potential for QT prolongation and proarrhythmia by
non-antiarrhythmic drugs: Clinical and regulatory implications Eur
Heart. J. 21:1216–1231. 2000.
|
|
8
|
Unnikrishnan D, Dutcher JP, Garl S,
Varshneya N, Lucariello R and Wiernik PH: Cardiac monitoring of
patients receiving arsenic trioxide therapy. Br J Haematol.
124:610–617. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sinha R, Kim GJ, Nie S and Shin DM:
Nanotechnology in cancer thearpeutics: Bioconjugated nanoparticles
for drug delivery. Mol Cancer Ther. 5:1909–1917. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrari M: Cancer nanotechnology:
opportunities and challenges. Nat Rev Cancer. 5:161–171. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sanna V, Pala N and Sechi M: Targeted
therapy using nanotechnology: focus on cancer. Int J Nanomedicine.
9:467–483. 2014.PubMed/NCBI
|
|
12
|
Song L: Preparation Method of
MaterialMaterials Introduction. Zhou DF: Chemical Industry Press;
Beijing: pp. 119–121. 2001
|
|
13
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mazel S, Burtrum D and Petrie HT:
Regulation of cell division cycle progression by bcl-2 expression:
a potential mechanism for inhibition of programmed cell death. J
Exp Med. 183:2219–2226. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Yang L and Qiao Z: An analysis of
the therapeutic effects and reactions in treating acute
promyelocytic leukemia with intravenous arsenic trioxide or
all-trans retinoic acid. Zhonghua Nei Ke Za Zhi. 38:113–115.
1999.(In Chinese). PubMed/NCBI
|
|
16
|
Liu L, Qin SK, Chen HY, Wang J, Chen H, Ma
J and Liu W: An experimental study on arsenic trioxide-selectively
induced human hepatocarcinoma cell lines apoptosis and its related
genes. Zhonghua Gan Zang Bing Za Zhi. 8:367–369. 2000.(In Chinese).
PubMed/NCBI
|
|
17
|
Huang SY, Chang CS, Tang JL, Tien HF, Kuo
TL, Huang SF, Yao YT, Chou WC, Chung CY, Wang CH, et al: Acute and
chronic arsenic poisoning associated with treatment of acute
promyelocytic leukemia. Br J Haematol. 103:1092–1095. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Ma L and Hu N: Ailing No. 1 in
treating 62 cases of acute promyelocytic leukemia. Zhongguo Zhong
Xi Yi Jie He Za Zhi. 19:473–476. 1999.(In Chinese). PubMed/NCBI
|
|
19
|
Wang MD, Shin DM, Simons JW and Nie S:
Nanotechnology for targeted cancer therapy. Expert Rev Anticancer
Ther. 7:833–837. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mathews V, George B, Lakshmi KM,
Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM,
Srivastava A and Chandy M: Single-agent arsenic trioxide in the
treatment of newly diagnosed acute promyelocytic leukemia: Durable
remissions with minimal toxicity. Blood. 107:2627–2632. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang YQ, Zhang YQ and Hua RQ: Preparation
and properties of LLDPE/ Nano SiO2 composites. Zhong Guo
Su Liao. 17:252003.(In Chinese).
|
|
22
|
Zhao K, Chao YL and Yang Z: Development
and property study of zirconia toughened nano-composite alumina
ceramic powder for dental application. Zhonghua Kou Qiang Yi Xue Za
Zhi. 38:384–386. 2003.(In Chinese). PubMed/NCBI
|
|
23
|
Wang ZY, Zhang DS, Lu XL, Yan SY, Jin LQ
and Wan ML: Research of human liver cancer cell apoptosis induced
by As2O3 nanoparticles. Yi Xue Yan Jiu Sheng
Bao. 18:481–489. 2005.(In Chinese).
|
|
24
|
Wang Q, Wang ZY, Lin M, Zhang J, Zhao SS
and Zhang DS: Application of As2O3
nanoparticles in treatment on human lung cancer in vivo and
investigation of its anti-transfer mechanism. Na Mi Ji Shu He Jing
Mi Gong Cheng. 6:99–102. 2008.(In Chinese).
|
